VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma
Table 2
Allelic and genotypic frequencies of VEGF-C936T and VEGF-A1154G polymorphisms in patients with hepatocellular carcinoma (G1), cirrhosis (G2), and individuals without the disease (G3).
(a) C936T
G1 ()
G2 ()
G3 ()
value
G1 × G3
G2 × G3
G1 × G2
Allele
AF
AF
AF
C
174
0.85
199
0.85
217
0.85
0.966
0.903
0.941
T
30
0.15
35
0.15
37
0.15
Genotype
(%)
(%)
(%)
Dominant
C/C
72
(71)
84
(72)
90
(71)
0.963
0.985
0.962
C/T + T/T
30
(29)
33
(28)
37
(29)
Heterozygote
C/T
30
(29)
31
(26)
37
(29)
0.963
0.751
0.742
C/C + T/T
72
(71)
86
(74)
90
(71)
Recessive
T/T
—
(0)
2
(2)
—
(0)
—
—
—
C/T + C/C
102
(100)
115
(98)
127
(100)
HW ()
3.03
0.20
3.69
>0.05
(b) A1154G
G1 ()
G2 ()
G3 ()
value
G1 × G3
G2 × G3
G1 × G2
Allele
n
AF
n
AF
n
AF
G
157
0.77
172
0.74
193
0.76
0.893
0.598
0.469
A
47
0.23
62
0.26
61
0.24
Genotype
(%)
(%)
(%)
Dominant
G/G
61
(60)
60
(51)
73
(57)
0.826
0.399
0.258
G/A + A/A
41
(40)
57
(49)
54
(43)
Heterozygote
G/A
35
(34)
52
(44)
47
(37)
0.776
0.293
0.164
A/A + G/G
67
(66)
65
(56)
80
(63)
Recessive
A/A
6
(6)
5
(4)
7
(6)
0.904
0.880
0.815
G/A + G/G
96
(94)
112
(96)
120
(94)
HW ()
0.74
2.32
0.02
>0.05
Fisher’s exact test or Chi-Square test (); = number of subjects; = number of alleles; AF = absolute frequency; HW = Hardy-Weinberg.
